The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.
 
Diane M. Simeone
Consulting or Advisory Role - Celgene
Research Funding - Abbvie
Patents, Royalties, Other Intellectual Property - small royalties for my patent on pancreatic cancer stem cells also I receive an annual royalty for a textbook I edited Greenfields Textbook of Surgery
Travel, Accommodations, Expenses - Konica Minolta Precision Medicine
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Gritstone Bio; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Gritstone Bio (Inst); Lilly (Inst); Merck (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Sandip Pravin Patel
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Certis Oncology Solutions; Compugen; Illumina; Lilly; Lilly; Merck; Nektar; Novartis; Pfizer; Roche/Genentech; Tempus
Speakers' Bureau - Boehringer Ingelheim; Merck
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Fate Therapeutics (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Maria Pia Morelli
No Relationships to Disclose
 
Kedar Kirtane
Stock and Other Ownership Interests - Agenus; Immunomedics; Macrogenics; Myovant Sciences; Oncternal Therapeutics; Seagen; Veru
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; Gilead Sciences; Intercept Pharmaceuticals; Spectrum Pharmaceuticals
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); De Novo Pharmaceuticals; Exelixis; Fujifilm (Inst); G1 Therapeutics; Genentech; Halozyme (Inst); Immunovative Therapies; Imvax; Inspyr Therapeutics; Insys Therapeutics (Inst); Klus Pharma; Lynx Group; Merck; Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Western Oncolytics
Research Funding - Adaptimmune (Inst); Agios (Inst); ARIAD (Inst); AstraZeneca (Inst); Basilea (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); Merck Serono (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); RedHill Biopharma (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene
 
Marcela Valderrama Maus
Leadership - 2seventy bio
Stock and Other Ownership Interests - 2seventy bio; Century Therapeutics; TCR2 Therapeutics; TCR2 Therapeutics
Consulting or Advisory Role - Adaptimmune; Agenus; arcellx; Astellas Pharma; AstraZeneca; Atara Biotherapeutics; Bayer; BMS; Cabaletta Bio; crispr therapeutics; GlaxoSmithKline; In8bio; Intellia Therapeutics; Kite, a Gilead company; MicroMedicine; Novartis; Sanofi; TCR2 Therapeutics; Tmunity Therapeutics, Inc.; Torque; windmil
Research Funding - CRISPR Therapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Servier (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patents held by Massachusetts General Hospital/Partners Health care; all related to CAR T cells and/or gene therapy; Inventor on patents held by U. Pennsylvania with and without Novartis
 
John B. Sunwoo
Employment - Hessler Plastic Surgery (I)
Leadership - Hessler Plastic Surgery (I)
Stock and Other Ownership Interests - Moderna Therapeutics; Pfizer
Consulting or Advisory Role - Indapta Therapeutics
Speakers' Bureau - Galderma (I)
Patents, Royalties, Other Intellectual Property - N.A. (Inst)
Travel, Accommodations, Expenses - Allergan (I); Galderma (I)
 
Theodore Welling
No Relationships to Disclose
 
Yi Lin
Consulting or Advisory Role - Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gamida Cell (Inst); Janssen Oncology (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Legend Biotech (Inst); Novartis (Inst); Pfizer (Inst); Sorrento Therapeutics (Inst); Vineti (Inst)
Research Funding - Bluebird Bio (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Merck (Inst); Takeda (Inst)
 
Edward B. Garon
Consulting or Advisory Role - ABL Bio; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Shionogi; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; MolecularMatch
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Xilis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Frederick L. Locke
Consulting or Advisory Role - Alimera Sciences; Amgen; Bluebird Bio; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Calibr; Celgene; Cellular Biomedicine Group; Cowen; Daiichi Sankyo/UCB Japan; EcoR1 Capital; Gerson Lehrman Group; Iovance Biotherapeutics; Janssen; Kite, a Gilead company; Legend Biotech; Novartis; Sana Biotechnology; Takeda; Umoja Biopharma
Research Funding - Alimera Sciences (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb/Celgene (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - CAR T Cells with Enhanced Metabolic Fitness. Serial Number: 62/939,727 (Inst); Double Mutant Survivin Vaccine. US010414810B2. (Inst); Evolutionary Dynamics of Non-Hodgkin Lymphoma CAR-T cell therapy. Serial Number: 62/879,534. (Inst); Methods of Enhancing CAR T Cell Therapies. Serial Number: 62/892,292. (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Kirstin B. Liechty
Employment - A2 Biotherapeutics
Stock and Other Ownership Interests - Stock options granted and vest over 4 years at time of hire.
Consulting or Advisory Role - Consulted for A2 Bio prior to joining the company through K2 Consulting Inc.
 
Ariane Lozac'hmeur
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Patents, Royalties, Other Intellectual Property - Tempus
 
Karl Beutner
Employment - Tempus
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Tempus
 
Eric Wai-Choi Ng
Employment - A2 Biotherapeutics; Amgen
Stock and Other Ownership Interests - A2 Biotherapeutics; Amgen
Travel, Accommodations, Expenses - A2 Biotherapeutics; Amgen
 
William Y. Go
Employment - A2 Biotherapeutics
Leadership - A2 Biotherapeutics
Stock and Other Ownership Interests - A2 Biotherapeutics; A2 Biotherapeutics; Gilead Sciences
Research Funding - A2 Biotherapeutics
Travel, Accommodations, Expenses - A2 Biotherapeutics
Other Relationship - American Pancreatic Association; Viewpoint School
 
David G. Maloney
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; Genentech/Roche; Gilead Sciences; Incyte; Janssen; Juno Therapeutics; Kite, a Gilead company; Legend Biotech; MorphoSys; MustangBio; Novartis; Pharmacyclics; Umoja Biopharma
Consulting or Advisory Role - A2 Biotherapeutics; Celgene/Bristol-Myers Squibb; Genentech; NAVAN Technologies
Research Funding - Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on 4 provisional patents.
 
Julian R. Molina
No Relationships to Disclose